• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.

作者信息

Bossi Elisa, Aroldi Andrea, Brioschi Filippo A, Steidl Carolina, Baretta Silvia, Renso Rossella, Verga Luisa, Fontana Diletta, Sharma Geeta G, Mologni Luca, Mussolin Lara, Piazza Rocco, Gambacorti-Passerini Carlo

机构信息

Hematology Division, San Gerardo Hospital, Monza, Italy.

Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

出版信息

Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3.

DOI:10.1002/ajh.25967
PMID:32808682
Abstract
摘要

相似文献

1
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.克唑替尼用于间变性淋巴瘤激酶（ALK）阳性间变性大细胞淋巴瘤化疗复发/难治患者的二期研究。
Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3.
2
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.艾乐替尼治疗复发或难治性间变性淋巴瘤激酶阳性间变大细胞淋巴瘤：一项开放标签的 II 期试验。
Cancer Sci. 2020 Dec;111(12):4540-4547. doi: 10.1111/cas.14671. Epub 2020 Oct 28.
3
Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.儿童间变性大细胞淋巴瘤（ALK 阳性）复发难治后应用 ALK 特异性酪氨酸激酶抑制剂治疗：病例系列研究
J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e1-e4. doi: 10.1097/MPH.0000000000002137.
4
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.克唑替尼用于复发或难治性间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤的I/II期研究及克唑替尼用于复发或难治性神经母细胞瘤的I期研究：一项多中心单臂开放标签试验的研究方案
Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184.
5
Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.阿来替尼和依维莫司对 ALK 阳性间变大细胞淋巴瘤生长抑制的协同作用。
Anticancer Res. 2020 Mar;40(3):1395-1403. doi: 10.21873/anticanres.14081.
6
ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.间变性淋巴瘤激酶（ALK）表达在间变性大细胞淋巴瘤中发挥不同作用，以及在中国人群复发/难治性ALK阳性患者中使用克唑替尼的疗效。
Ann Hematol. 2018 Jan;97(1):149-159. doi: 10.1007/s00277-017-3166-8. Epub 2017 Nov 17.
7
Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).克唑替尼与化疗联合用于复发或难治性间变性淋巴瘤激酶（ALK）阳性间变性大细胞淋巴瘤（ALCL）患者。
Leuk Lymphoma. 2021 Mar;62(3):571-580. doi: 10.1080/10428194.2020.1839658. Epub 2020 Nov 6.
8
ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.原发性间变性大细胞淋巴瘤中ALK激酶结构域突变：对NPM-ALK活性及酪氨酸激酶抑制剂敏感性的影响
PLoS One. 2015 Apr 13;10(4):e0121378. doi: 10.1371/journal.pone.0121378. eCollection 2015.
9
Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.阿来替尼治疗难治性间变性淋巴瘤激酶重排间变性大细胞淋巴瘤
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e247-e250. doi: 10.1016/j.clml.2019.03.001. Epub 2019 Mar 11.
10
Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.采用脐带血进行二次同种异体移植治疗 ALK 阳性间变大细胞淋巴瘤患者：ALK 抑制剂时代的 1 例病例报告。
Medicine (Baltimore). 2021 Apr 16;100(15):e25576. doi: 10.1097/MD.0000000000025576.

引用本文的文献

1
Anaplastic large cell lymphoma in children and adolescents.儿童和青少年间变性大细胞淋巴瘤
Br J Haematol. 2025 Aug;207(2):336-349. doi: 10.1111/bjh.20154. Epub 2025 May 12.
2
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.外周T细胞和自然杀伤细胞淋巴瘤：ESMO-EHA诊断、治疗及随访临床实践指南
Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May.
3
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶：从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
4
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia.发现用于治疗急性髓系白血病的选择性、代谢稳定的吡唑类FLT3抑制剂。
RSC Med Chem. 2025 Jan 30. doi: 10.1039/d4md00956h.
5
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.间变性淋巴瘤激酶（ALK）抑制剂增强了CD47阻断在敏感和耐药的ALK驱动恶性肿瘤中诱导的吞噬作用。
Biomedicines. 2024 Dec 12;12(12):2819. doi: 10.3390/biomedicines12122819.
6
Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.外周T细胞淋巴瘤的进展：发病机制、基因图谱及新兴治疗靶点
Histopathology. 2025 Jan;86(1):119-133. doi: 10.1111/his.15376.
7
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.FAT 家族钙黏蛋白的反复体细胞突变导致间变大细胞淋巴瘤表现出侵袭性表型和不良预后。
Br J Cancer. 2024 Dec;131(11):1781-1795. doi: 10.1038/s41416-024-02881-7. Epub 2024 Oct 30.
8
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.复发/难治性外周 T 细胞淋巴瘤的新型临床风险分层和治疗策略。
J Hematol Oncol. 2024 Jun 1;17(1):38. doi: 10.1186/s13045-024-01560-7.
9
How molecular advances may improve the diagnosis and management of PTCL patients.分子学进展如何改善外周T细胞淋巴瘤（PTCL）患者的诊断与管理。
Front Oncol. 2023 Jun 23;13:1202964. doi: 10.3389/fonc.2023.1202964. eCollection 2023.
10
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.靶向 CCR7-PI3Kγ 克服 ALK 重排淋巴瘤对酪氨酸激酶抑制剂的耐药性。
Sci Transl Med. 2023 Jun 28;15(702):eabo3826. doi: 10.1126/scitranslmed.abo3826.